本帖最后由 老马 于 2012-1-13 21:20 编辑
$ ]" a! `0 X7 `: k$ k; P" [& K- V9 v! l1 H$ P- T7 S' P1 c: p! Y q
爱必妥和阿瓦斯丁的比较) M5 f/ X8 o5 @- {! j6 E
+ [: D( a- e; ~: Y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' t. G3 O, {% D/ n1 X
, L: K( Q' Z1 c1 c+ _ ]
5 h1 i- q* q0 e" E/ G5 I1 }
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
/ h0 s; w2 W& E+ Z: \==================================================4 d G1 ]3 T# e, Y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); ?' p+ ~: m2 o# S& h; z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. R+ n: O& m2 n$ A0 s
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
6 a9 p& q4 {$ S6 L0 Z0 b) [1 {
|